thalidomide has been researched along with Acrodermatitis in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Acrodermatitis: Inflammation involving the skin of the extremities, especially the hands and feet. Several forms are known, some idiopathic and some hereditary. The infantile form is called Gianotti-Crosti syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Apremilast is an oral phosphodiesterase 4 inhibitor, approved for the treatment of chronic plaque psoriasis and psoriatic arthritis." | 5.51 | Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast. ( Bianchi, L; Campione, E; Cesaroni, GM; Diluvio, L; Lanna, C; Lozzi, F; Mazzilli, S; Palumbo, V, 2019) |
| "Apremilast is an oral phosphodiesterase 4 inhibitor, approved for the treatment of chronic plaque psoriasis and psoriatic arthritis." | 1.51 | Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast. ( Bianchi, L; Campione, E; Cesaroni, GM; Diluvio, L; Lanna, C; Lozzi, F; Mazzilli, S; Palumbo, V, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Megna, M | 1 |
| Potestio, L | 1 |
| Di Caprio, N | 1 |
| Tajani, A | 1 |
| Fabbrocini, G | 1 |
| Annunziata, A | 1 |
| Fusta-Novell, X | 1 |
| Esquius, M | 1 |
| Creus-Vila, L | 1 |
| Calleja Algarra, A | 1 |
| Aragón Miguel, R | 1 |
| Velasco Tamariz, V | 1 |
| Prieto Barrios, M | 1 |
| Andrés Lencina, JJ | 1 |
| Vico Alonso, C | 1 |
| Ortiz Romero, PL | 1 |
| Rivera Díaz, R | 1 |
| Lanna, C | 1 |
| Cesaroni, GM | 1 |
| Mazzilli, S | 1 |
| Lozzi, F | 1 |
| Palumbo, V | 1 |
| Diluvio, L | 1 |
| Bianchi, L | 1 |
| Campione, E | 1 |
| Kurihara, Y | 1 |
| Nakano, K | 1 |
| Eto, A | 1 |
| Furue, M | 1 |
5 other studies available for thalidomide and Acrodermatitis
| Article | Year |
|---|---|
Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?
Topics: Acrodermatitis; Exanthema; Humans; Psoriasis; Skin Diseases, Vesiculobullous; Thalidomide | 2022 |
Rapid and sustained response to apremilast in a patient with long-standing acrodermatitis continua of Hallopeau.
Topics: Acrodermatitis; Exanthema; Humans; Psoriasis; Thalidomide | 2022 |
Apremilast as a new treatment option for Acrodermatitis continua of Hallopeau.
Topics: Acrodermatitis; Aged; Anti-Inflammatory Agents, Non-Steroidal; Humans; Male; Thalidomide | 2019 |
Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast.
Topics: Acrodermatitis; Anti-Inflammatory Agents, Non-Steroidal; Humans; Male; Middle Aged; Nail Diseases; T | 2019 |
Successful treatment of acrodermatitis continua of Hallopeau with apremilast.
Topics: Acrodermatitis; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Fingers; Humans; Male; Middle A | 2019 |